EUR 2.38
(-0.42%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 6.6 Million EUR | -58.6% |
2022 | 13.83 Million EUR | 567.03% |
2021 | -2.96 Million EUR | -202.57% |
2020 | 2.88 Million EUR | -19.11% |
2019 | 3.57 Million EUR | 144.56% |
2018 | 1.45 Million EUR | 54.76% |
2017 | 943.34 Thousand EUR | 70.61% |
2016 | 552.93 Thousand EUR | -51.67% |
2015 | 1.14 Million EUR | -48.98% |
2014 | 2.24 Million EUR | -76.74% |
2013 | 9.63 Million EUR | -13.12% |
2012 | 11.09 Million EUR | 94.23% |
2011 | 5.71 Million EUR | 0.0% |
2010 | - EUR | -100.0% |
2009 | 10 Million EUR | 0.0% |
2008 | - EUR | 0.0% |
2007 | - EUR | 0.0% |
2006 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 1.01 Million EUR | -64.11% |
2024 Q2 | 1.24 Million EUR | 22.13% |
2024 Q3 | 1.05 Million EUR | -15.56% |
2023 Q2 | 801.81 Thousand EUR | 28.28% |
2023 Q1 | 625.05 Thousand EUR | -81.29% |
2023 Q3 | 2.11 Million EUR | 164.17% |
2023 Q4 | 2.84 Million EUR | 34.13% |
2023 FY | 5.72 Million EUR | -58.6% |
2022 Q4 | 3.34 Million EUR | 61.97% |
2022 Q1 | 85.19 Thousand EUR | 108.2% |
2022 Q2 | 8.34 Million EUR | 9696.56% |
2022 Q3 | 2.06 Million EUR | -75.29% |
2022 FY | 13.83 Million EUR | 567.03% |
2021 Q1 | -705.73 Thousand EUR | -395.74% |
2021 Q3 | -807 Thousand EUR | -96.59% |
2021 Q4 | -1.03 Million EUR | -28.75% |
2021 Q2 | -410.51 Thousand EUR | 41.83% |
2021 FY | -2.96 Million EUR | -202.57% |
2020 Q1 | -8885.00 EUR | -106.07% |
2020 FY | 2.88 Million EUR | -19.11% |
2020 Q2 | 497.39 Thousand EUR | 5698.09% |
2020 Q3 | 2.54 Million EUR | 411.07% |
2020 Q4 | -142.36 Thousand EUR | -105.6% |
2019 FY | 3.57 Million EUR | 144.56% |
2019 Q1 | 382.05 Thousand EUR | 220.83% |
2019 Q2 | 1.39 Million EUR | 266.14% |
2019 Q3 | 1.64 Million EUR | 17.45% |
2019 Q4 | 146.36 Thousand EUR | -91.09% |
2018 Q1 | 215.24 Thousand EUR | 68.99% |
2018 Q2 | 1 Million EUR | 369.2% |
2018 FY | 1.45 Million EUR | 54.76% |
2018 Q4 | -316.2 Thousand EUR | -157.4% |
2018 Q3 | 550.89 Thousand EUR | -45.45% |
2017 FY | 943.34 Thousand EUR | 70.61% |
2017 Q3 | 377.37 Thousand EUR | 119.76% |
2017 Q4 | 127.37 Thousand EUR | -66.25% |
2017 Q2 | 171.71 Thousand EUR | -35.66% |
2017 Q1 | 266.88 Thousand EUR | 2994.61% |
2016 Q2 | -1.79 Million EUR | -721.22% |
2016 Q3 | 23.6 Thousand EUR | 101.32% |
2016 FY | 552.93 Thousand EUR | -51.67% |
2016 Q1 | 288.46 Thousand EUR | -25.54% |
2016 Q4 | -9220.00 EUR | -139.06% |
2015 Q2 | -1.33 Million EUR | -2342.58% |
2015 FY | 1.14 Million EUR | -48.98% |
2015 Q1 | 59.48 Thousand EUR | -90.08% |
2015 Q4 | 387.4 Thousand EUR | 252.79% |
2015 Q3 | 109.81 Thousand EUR | 108.23% |
2014 FY | 2.24 Million EUR | -76.74% |
2014 Q4 | 599.55 Thousand EUR | -55.75% |
2014 Q3 | 1.35 Million EUR | 220.04% |
2014 Q2 | 423.32 Thousand EUR | 411.4% |
2014 Q1 | -135.94 Thousand EUR | -104.19% |
2013 Q4 | 3.24 Million EUR | 30.06% |
2013 FY | 9.63 Million EUR | -13.12% |
2013 Q1 | 2 Million EUR | -57.07% |
2013 Q2 | 1.9 Million EUR | -5.02% |
2013 Q3 | 2.49 Million EUR | 30.92% |
2012 FY | 11.09 Million EUR | 94.23% |
2012 Q1 | 2.18 Million EUR | 19.02% |
2012 Q2 | 3.5 Million EUR | 60.27% |
2012 Q3 | 4.14 Million EUR | 18.33% |
2012 Q4 | 4.66 Million EUR | 12.61% |
2011 Q1 | -251.68 Thousand EUR | 0.0% |
2011 Q3 | 3.37 Million EUR | 160.25% |
2011 Q2 | 1.29 Million EUR | 614.71% |
2011 FY | 5.71 Million EUR | 0.0% |
2011 Q4 | 1.83 Million EUR | -45.53% |
2010 FY | - EUR | -100.0% |
2010 Q2 | 348.5 Thousand EUR | -38.21% |
2010 Q3 | - EUR | -100.0% |
2010 Q1 | 563.97 Thousand EUR | -88.72% |
2010 Q4 | - EUR | 0.0% |
2009 Q4 | 5 Million EUR | 0.0% |
2009 Q3 | 5 Million EUR | 648.73% |
2009 Q2 | 667.79 Thousand EUR | 41.95% |
2009 Q1 | 470.44 Thousand EUR | 0.0% |
2009 FY | 10 Million EUR | 0.0% |
2008 FY | - EUR | 0.0% |
2007 FY | - EUR | 0.0% |
2006 FY | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
BioNTech SE | 3.21 Billion EUR | 99.795% |
CureVac N.V. | -70.6 Million EUR | 109.356% |
Biotest Aktiengesellschaft | 271.9 Million EUR | 97.57% |
Biotest Aktiengesellschaft | 271.9 Million EUR | 97.57% |
BRAIN Biotech AG | 30.12 Million EUR | 78.069% |
Formycon AG | 23.3 Million EUR | 71.654% |
Medigene AG | 4.39 Million EUR | -50.446% |